Barriers to a clinical "Test Once, Analyze Many" molecular DNA strategy.

Question

[bdolin]

Given the dropping costs of WGS/WES, the maturation of public knowledgebases (such as [https://www.clinicalgenome.org/]), and the drive for precision medicine (where for instance there may be new or different things to glean from someone's DNA over time), there is an evolving use case whereby a clinician would test a person's DNA once, and then access raw data (e.g. complete VCF file) many times - as a new drug is prescribed, as new genetic risk factors are determined, etc.

Are EHRs doing this today?

I’m curious to know what barriers are being encountered or perceived. Thanks

[Pierre Lindenbaum]

EHR: Electronic Health Record